A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia

Published:1999-09 Issue:9 Volume:23 Page:787-794
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Karanes Chatchada,Kopecky Kenneth J,Head David R,Grever Michael R,Hynes Harry E,Kraut Eric H,Vial Richard H,Lichtin Alan,Nand Sucha,Samlowski Wolfram E,Appelbaum Frederick R

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference15 articles.

1. High-dose cytosine arabinoside therapy for refractory leukemia;Herzig;Blood,1983

2. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia;Herzig;J. Clin. Oncol.,1985

3. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults;Philips;Blood,1991

4. Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemia;Hines;Semin. Oncol.,1987

5. A randomized investigation of high dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology group study;Weick;Blood,1996

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML;Leukemia Research;2024-05

2. Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?;Journal of Clinical Medicine;2024-01-18

3. Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial;Frontiers in Oncology;2023-08-18

4. Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML;OncoTargets and Therapy;2023-06

5. A review of treatment options employed in relapsed/refractory AML;Hematology;2023-04-10